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Abstract
New treatments for cancer are continuously being developed and improved. One
such treatment is Photodynamic Therapy, more commonly referred to as PDT. PDT is
quickly becoming more popular due to its relative lack of side effects that are present in
other treatments. In PDT, light-sensitive agents are required and are activated by light in the
targeted cells. There are many types of PDT agents but the one focused on in this research is
a four-pyrrole ring structure known as a porphyrin 1• The combination of H2 TPPC with 3amino-oxetane-3-yl-methanol created the final product ofH2TPP-Oxo-MeOH. Once the
porphyrin was formed, it was then characterized using infrared spectroscopy (IR), UV -vis
spectroscopy, and nuclear magnetic resonance (NMR). Its photocytotoxicity or its effect on
cell death in triple-negative breast cancer cells, specifically MDA-MB-231, was tested using
an MTT Assay with two conditions, dark and light.
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Introduction
Cancer is something that is relatively common and will affect approximately 38.4%
of people at some point in their life2 . Since its discovery, researchers have spent years
distinguishing its forms and developing new and more effective diagnostic techniques as
well as treatments. The rate of cancer survival has only increased as scientific research in the
area has progressed. Since it is a disease that affects so many people, there are thousands of
fundraising events and billions of dollars are donated to continue the research. Cancer
therapy and treatment is an area that is constantly being researched and improved in many
ways. The most common form of cancer treatments are chemotherapy or radiation. These
treatments not only lack the ability to target certain cells but also may cause many severe
side effects. They can also lead to many complications that can actually hinder a patient's
healing and decreases their quality of life3 . A newer form of therapy known as
photodynamic therapy lacks the side effects that chemotherapy has while also being able to
target specific cells within the body.

Background
Triple Negative Breast Cancer
Triple- Negative Breast Cancer (TNBC) is named as such because this type of cancer
does not have the markers for estrogen (ER), progesterone (PR), and HER2. Simply put,
TNBC does not have those hormone receptors present and therefore does not respond to
typical anti-hormonal treatments. In the beginning, researchers thought that all breast
cancers were the same4 . With advances in science came new ways to test cancer and read
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genes. Because of these advances, researchers learned that not all breast cancer is the same
and have been developing new ways to treat each type of breast cancer. While anyone can
develop breast cancer, it has been found that young women, African American women, and
BRCAJ mutation carriers are at a greater risk for developing TNBC than other groups of

people 5' 6• Around 70%-90% of cases of TNBC have a basal-like genetic pattern. Simply
put, this means that the cancer cells look similar to the cells that line the breast ducts. They
typically over express genes that encourage the growth of these cancer cells4 .

Treatments
In order to treat Triple Negative Breast Cancer, there are five different options. The
first is a lumpectomy. As its name suggests, a surgeon will simply remove the lump from the
breast and check to make sure cancer has not spread. A mastectomy is similar to the first but
it removes the entire breast rather than a part. The next two treatments, chemotherapy and
radiation tend to have similar impacts on the body7• Chemotherapy utilizes different drugs to
target any rapidly growing cell. Due to its lack of specificity, it also targets rapidly growing
healthy cells such as hair cells and the lining of the intestinal tract3 • Radiation is similar to
chemotherapy but rather than a drug, it uses high-energy radiation and is site-specific. It has
very similar side effects to chemotherapy7• A more recently developed treatment for cancer
is that of photodynamic therapy (PDT). Unlike other types of treatment, it is minimally
invasive, targeted, and limited in its side effects.

Development of Photodynamic Therapy
The idea of photodynamic therapy has been around since ancient Greece but was lost
until 1841 with the discovery of hematoporphyrin. Phototoxicity, which is the death of cells
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after exposure to a chemical and then light, was discovered in a study done from 1861-1871.
Further studies were done and in 1903 N.R. Finsen received the Nobel Prize for
Phototherapy9 . Porphyrins, which are photosensitizing agents used in PDT, were examined
in 1925 by H. Fischer9 . The basis for the modem version of PDT was the hematoporphyrin
derivative (HpD) study done in 1960 by Lipson, et a1 9 • Photodynamic therapy has three
functional elements that are necessary to its effectiveness. The first is a photosensitizer. This
can be a drug, such as a porphyrin, or another small molecule that is used to target cancer
cells and is activated by light. The next element is an optical wavelength of light. This is the
trigger for the photosensitizer to interact with oxygen and release the chemical necessary for
cell death. Wavelength can vary depending on what drug is used and what researchers are
trying to investigate. The last element is molecular oxygen. This element is tied to the
photosynthesizer and is required to create an oxygen radical species needed to initiate cell
death 10 .

PDT in Practice
Pros and Cons of PDT
When debating photodynamic therapy as a treatment, it becomes necessary to
examine both the positives and negative of the treatment. The biggest advantage of PDT is
that it has no lasting side effects. Unlike chemotherapy and radiation, PDT is relatively easy
on the body as a whole. It also less invasive and is a quicker outpatient option. Many
treatments, such as radiation or surgery, require long stays in the hospital that can be very
draining on the patient. PDT' s use of light and light sensitive agents allows it to target
certain areas in the body. Because it is easier on the body, it can be repeated many times in
the same area. One of the biggest pros for PDT is its affordability. Financial burden is
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something that many people who have cancer struggle with. The cost for the more common
cancer treatments and hospital stays is more than most people can afford.
While Photodynamic Therapy has a long list ofbenefits in its favor, it also has its
drawbacks. Due to its use of photosensitive agents, some people can be affected by the sun
after treatment. Therefore, extra precaution must be taken to remain out of direct sunlight
until the agents have left the patient's system. PDT is also limited in areas that it can reach
within the body. It can only treat tumors that can be reached with a light source. It is also not
able to treat cancers that have spread to many areas within the body. Lastly is the fact that
individuals with certain diseases cannot receive the agents used in PDT. One such case is
those with porphyria. Porphyria is a rare blood disease that affects the skin and is a result of
the build up of naturally produced porphyrins. In extrememly rare cases, people can be
allergic to the porphyrins used in the treatment 10 .

How PDT Works
Photodynamic Therapy is a treatment that utilizes light and photosensitizing agents
to target and kill cancer cells. The agent or drug can be administered one of two ways,
through an injection or topically. How it is administered is dependent on the location of the
cancer cells. Once the cancer cells absorb the agent, it can be activated by light. After being
activated, it interacts with oxygen to create a singlet oxygen species that kills cancer cells.
Depending on the drug used, the drug-to-light interval or the time between when the patient
receives that drug and when the light can be applied ranges from two hours to two days 9' 10 .
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FIGURE: 1
The procedure used in PDT 11
(https://www.ncbi.nlm.nih.gov/prnc/articles/PMC3475217/)
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FIGURE: 2
Process of cell death after activation of the Photosensitizer 11
(https://www.ncbi .nlm.nih.gov/pmc/articles/PMC3475217/)

Health Problems Treated with PDT
While cancer is the main issue that is treated with Photodynamic Therapy, it is also
used to treat different skin problems. These issues include sun damage, acne, signs of aging
and many more. The basic process of PDT is the same no matter what is being treated; the

Page
types of drugs and light wavelength change. When dealing with skin issues, Levulan and
blue light are used. Levulan contains the active ingredient 5-aminolevulinic acid
hydrochloride which acts as the photosensitizing agent 12 .

FIGURE: 3
Example of PDT using blue light 12
(https://www.medicinenet.com/photodynamic therapy/article.htm)

FIGURE: 4
Before and After PDT 13
(https://clderm.com/ procedure/photodynam ic-therapyO

I

13

Page

I

14

Future of PDT
As the research in the area of Photodynamic therapy continues, more health
problems may be able to receive this treatment and it will become more effective as time
goes on. Some doctors even use PDT to treat issues such as actinic keratosis and certain eye
conditions such as macular degeneration. While this treatment has not been approved by the
FDA to treat all types of cancer, it has been approved for some and has also been approved
for different medical trials. Another area of improvement for PDT is the development of
novel photodynamic agents. These future drugs may be able to target tumors that are even
deeper in the body as well as become more directed in the targeting of cancer cells as
opposed to healthy cells. The next area of change would occur in the light source itself. This
specifically looks at the use of light in differing doses in order to limit the side effects. The
final area that researchers are looking at is the combination of PDT and other existing
treatments in order to make it more effective. If research into PDT continues, it potentially
may become the primary cancer treatment in many cases, replacing the existing versions of
chemotherapy and radiation as treatments.

Materials and Methods
Research Overview
In this research, a novel light-absorbing compound was created. This compound,
known as a porphyrin, can be activated by light photons and be used to target specific cells.
The two most important factors in this research were that the new PDT agent created was
water-soluble and had a negative impact on the growth ofTNBC cells when exposed to
light. The goal of this project was to create a porphyrin using the amine, 3-amino-oxetane-3-
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yl methanol that would accomplish the two requirements listed above.

Porphyrin Synthesis
The synthesis of the porphyrin compounds can be described in three steps. In the first
step, 4-carboxybenzaldehyde reacts with pyrrole in propionic acid to form H2 TPPC (3). The
H2 TPPC from step one was then reacted with thionyl chloride (SOC h) in
dimethylformamide (DMF) to form H2TPPCl ( 4) in step two. In the final reaction, the acid
chloride was reacted with 3-amino-oxetane-3-yl methanol in methanol to create the final
porphyrin product H2TPP-Oxo-MeOH (5) which was used in the rest of the study.

OH

0
FIGURE: 5
3-amino-oxetane-3-yl-methanol
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FIGURE: 6
Pyrrole (1) reacts with 4-carboxybenzaldehyde (2) in propionic acid to form H2TPPC (3)
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FIGURE: 7
H2TPPC (3) from step 1 reacts with SOCh in DMF to create H2TPPCl (4)
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Reaction 3

(4)

H2TPP-3-0xe-McQH

(5)

FIGURE: 8
The acid chloride intermediate (4) reacts with 3-amino-oxetane-3-yl-methanol in methanol
to form HzTPP-Oxo-MeOH (5)

H2 TPPC Synthesis
In order to create a water-soluble compound using the amine (3-amino-oxetane-3-ylmethanol) the starting material Hz TPPC first had to be synthesized. The first step in this
process was to add 3.00g of 4-carboxybenzaldehyde (2.0x10-2 mol) to a clean, dry 500 mL
round-bottom flask with a stir bar. After the flask was placed on the heating mantle, 200 mL
of propionic acid was added. With the aid of a syringe, approximately 1.4mL of pyrrole
(4.8x10-2 mol) was then added to the mixture. After all three compounds were in the flask,
the flask was wrapped in aluminum foil and allowed to reflux for 1 hour. The aluminum foil
was necessary to protect the reaction from light. After an hour, the reaction was removed
from the heat and left to cool. After the flask and its contents cooled completely, parafilm
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was placed over the opening and it was placed in the freezer overnight to crystalize.
The following day, the compound was filtered using a medium sintered glass filter
and dichloromethane was used to wash the product, H2TPPC (3). The filter and the
compound were left to air-dry overnight. At this point, the compound was purple/black in
color.

H2 TPP-Oxo-MeOH Synthesis
In order for the amine to attach to the porphyrin, an acid chloride intermediate
needed to be created. This reaction is not only air sensitive but water sensitive as well. In
order to limit any possible interference, all the glassware was placed in an oven to dry
overnight. To start this reaction, 0.13g ofH2TPPC (1.64x10-4 mol) was measured and placed
in a 50 mL round bottom flask. The flask was then placed under a nitrogen sparge in order to
keep the environment dry. A stir bar and 10 mL ofDMF (dimethylformamide) were added
to the flask to dissolve the H2TPPC. The mixture was stirred under N2 sparge for 1 hour
after using a syringe to add 0.15 mL of SOCh (thionyl chloride, 2.06x1 o-3 mol). A green
product (H2 TPPCl) was formed.
Once the reaction had stirred for an hour, it was removed from the nitrogen sparge
and placed on a rotary evaporator or rotovap with the help of KECK clips. The purpose of
this step was to remove the DMF solvent and to leave the desired product behind. This
process was done by heating the mixture under vacuum. The flask and its contents remained
on the rotovap until it was completely dry. The flask with the dried acid chloride
intermediate (4) was then kept under vacuum overnight. The product in the flask was dark
and shimmery green color.
For the final reaction, fresh methanol was distilled. The flask was moved from the
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vacuum and placed back under a nitrogen sparge. 0.25g of the amine 3-amino-oxetane-3-ylmethanol (2.42x10-3 mol, Figure 5), and 25 mL of the methanol were added to a clean, glass
vial. The mixture was transferred to the flask containing the acid chloride intermediate and
was then stirred for an hour. Once the time was finished, the methanol was removed under
vacuum. The final product H2TPP-Oxo-MeOH (5) was dark purple in color.
This process was repeated three times in order to obtain a sufficient amount of
product. Once these three syntheses were achieved, the final productwas purified using
column chromatography.

Purification of the Porphyrin
In order to purify the porphyrin a process known as column chromatography was
used. Chromatography is used to separate various components of mixtures. The column is
broken down into two specific areas. The top is liquid (mobile phase) and is used to push the
compound through the solid (stationary phase) bottom half. The mixture is separated into
different components based on how it interacts with the stationary phase (Figure 9). The
stationary phase is placed in the column to separate the impure product 14 •
The first column was prepared by filling a glass column with Sephadex LH-20 and
using 50:50 methanol/water MeOH-H20 as the column material. The second column was
prepared in the same way but used Sephadex G-50 and Milli-Q H20 as the column material.
Before the impure porphyrin product was placed in the first column, it was first
filtered through a 0.45 mm nylon syringe filter to purify it. The desired porphyrin product
was a dark purple/pink color and paying close attention to the columns was necessary in
order to collect only the desired material. After passing through the column, the desired
fractions, recognized by their color, were rotovaped. After the purification process was
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complete, UV-vis and 1H-NMR spectroscopy were used to characterize the purified
porphyrin (5).

FIGURE: 9
The LH-20 column

FIGURE: 10
The G-50 column

Results
UV -vis Spectroscopy
To determine the absorbance ofthe product, Ultraviolet-Visible Spectroscopy (UVvis) was used. The wavelength of light recorded is determined by the excitation of the
electrons in the sample. Excitation occurs when molecules absorb the energy in the form of
light. Through the use of a prism, this device is able to separate the wavelengths after a
beam of light is emitted. The intensity is then measured by electronic detectors and
compared to the control sample. The light spectrum consists of visible light, which ranges
from 350 to 800 nm and ultraviolet light which ranged from 200 to 350 nm. A typical
porphyrin will have a "Soret" band at a wavelength of 415 nm. It will generally have "finger
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print" absorptions in the 500 to 750 nm range. These are sometimes referred to as the Q
Bands 15•16 . In the synthesized porphyrin, the Soret band appeared at 415 nm. The sample
was later diluted to a 30mM solution and eventually a 10 mM and 1 mM stock solutions for
the use in an MTT Assay.

Detector

Monochromator
Sample

Exit slit

Dispersion
device

Source

0

Entrance
slit

FIGURE: 11

This above diagram is an example of UV -vis spectroscopy and how light would pass
through the monochromator, the sample and be processed by the detector. 17
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FIGURE: 12
UV -vis spectra results for porphyrin H2 TPP-Oxo-MeOH. The epsilon values were calculated
with Beer's Law: A = cCl
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Infrared Spectroscopy
The use of infrared light in the reading of absorption, and emission of a molecule is
known as Infrared Spectroscopy (IR). This is done through the reading of the vibrations that
occur by the atoms in the molecule 18 . TheIR results (Figure 14) show that the H2TPP-OxoMeOH contains the amide bands (1577 cm- 1, 1534 cm- 1, and 1378 cm- 1), indicating that the
amine has been attached to the porphyrin.

FIGURE: 13
3-amino-oxetane-3-yl methanol IR spectra results
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FIGURE: 14
HzTPP-Oxo-MeOH IR spectra results

NMR Spectroscopy
NMR or Nuclear Magnetic Resonance Spectroscopy looks at organic molecules that
contain hydrogen atoms and helps to characterize them. The sample is tested in an NMR
tube, which is simply a thin, glass tube. The sample is dissolved in an appropriate solvent
and placed in the 1H NMR tube. The sample is then placed in a spinning holder that is
surrounded by a magnet 19 • The 1H NMR results are shown in Figure 15 and 16 for the amine
and the desired porphyrin. The NMR (Figure 16) results for the porphyrin created in this
research show that the desired porphyrin was produced by identifying the aromatic region of
the spectra, 6.5-8.0 ppm.
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FIGURE: 15

3-amino-oxetane-3-yl-methanol 1H-NMR in CDCb results
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FIGURE:16

H2TPP-Oxo-MeOH 1H-NMR in D20 results

MTT Assay of TNBC
While PDT is gaining popularity as a cancer treatment, it is not the primary treatment
used. It is used when there are no better options available. As mentioned earlier, Triple
Negative Breast Cancer lacks the three most common receptors that are the targets of some
cancer treatments. This is why PDT could potentially be used for treating those with TNBC.
Once the porphyrin was synthesized, purified, and characterized it was tested with
TNBC cells to determine its phototoxicity effectiveness. This was done to see ifH2TPP-
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Oxo-MeOH could be used in photodynamic therapy. The specific cell type used in this
project was MD-MBA 231 TNBC. The cells were grown and then plated onto two 96 wellplates. One plate was labeled "dark" (Figure 18) and the other was labeled "light" (Figure
17). The cells were allowed to grow for 72 hours in the wells. At the end of 72 hours, the
H2TPP-Oxo-MeOH was added in varying concentrations to each of the wells containing
MD-231 cells. Eight wells were treated with each concentration. Exposure to light was
minimized by covering the well-plate with aluminum foil. The cells were then incubated
overnight. The next day, the plate titled "light" received a media change and was exposed to
white light for 20 minutes (1/2 J/cm2). The plate was placed back in the incubator under
aluminum foil. The dark plate never received light and therefore only received a media
before being placed back in the incubator under aluminum foil. The plates incubated for
another 72 hours. At the end of this time, the phototoxicity was determined using MTT
assay and the amount of purple in the cells was quantified through spectrophotometries.

MTT Assay Results
Cell viability is commonly tested through MTT assays. The assay occurs in several
steps. The yellow MTT turns a purple color when living cells are present since
mitochondrial succinate dehydrogenzase catalyzes the formation of the purple MTTformazan. So, the darker the color, the greater the number of living cells. Since there was
some color difference between the "light" (Figure 17) and "dark" (Figure 18) plates, this
indicated that there was more cell death in those well-plates exposed to light.
Normally, a difference in color would be able to be seen amongst the different
concentrations due to the increase in cell death but that is not accurate in this case. The
percent of cell death was so little that there was no clear color change. When looking at
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figures (Figures 17 and 18), there are seven vertical columns that are important. The first is a
negative control. The wells in this column contain only TNBC cells and media. The next
column is another control but it contains DMSO in order to exclude it as a reason for cell
death. Columns 3 through 7 contain varying concentrations of(S). These rows contain 1, 3,
10, 30, and 74 f..!molar concentrations. The remaining rows contain more negative controls.
In order to make sure that the porphyrin is being triggered by light, the "dark" plate is used
as another control to compare to the amount of cell death on the "light" plate.

FIGURE: 17
The photo above is of the "light" plate with its varying rows marked. Color difference
among the column signals cell death.
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FIGURE: 18
The photo above is of the "dark" plate with the rows marked.
The MTT assay was run three different times in order to confirm the results. This
experiment showed that among the lower concentrations, there was little variation between
the two plates. The only condition to really see a slight difference was the 74 J..Lmol
concentration. While the light plate showed more cell death, it never reached the 50% cell
death mark that was anticipated.
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FIGURE: 19
Results of the second MTT assay. They-axis is the percent viability of the cells and the xaxis is the varying concentrations of (5).

Conclusion
The synthesis and characterization of a novel water-soluble porphyrin was
accomplished. The porphyrin contained the spectroscopic characteristics that were expected.
While it had the predicted porphyrin characteristics, it did not have the desired results as a
potential PDT agent. It was expected that there would be a significant difference between
the light and dark conditions as well as an increase in cell death among the varing
concentrations of porphyrin. It is unclear if it is the structure of the amine on the porphyrin
periphery that caused the porphyrin to be less effective or if other factors may play a role.
Future research studies should repeat these MTT assay experiments to confirm the results or
synthesize a more effective compound.
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